EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2019.12.16
CanSinoBIO's NDA for Investigational Quadrivalent Meningocococcal Conjugate Vaccine Granted with Priority Review Designation
2019.11.26
CanSinoBIO and TMPA Collaborate to Strengthen Regulatory Capabilities on Vaccine Surveillance Inspection
2019.11.22
CanSinoBIO Announces NMPA Acceptance for Its New Drug Application for Investigational Quadrivalent Meningococcal Vaccine
2019.08.26
China Peacekeepers Get Ebola Vaccine Shots Ahead Missions In DRC
2019.06.20
CanSinoBIO Joins Hands with BIRD-C to Explore BGs Based Vaccine Solutions
2019.04.19
CanSinoBIO Receives Approval for Its 13-Valent Penumococcal Conjugate Vaccine to Start Clinical Trials
2019.03.28
CanSinoBio First Day Debut on the Main Board of SEHK Total Turnover of Approximately HK$820 million Closing Price Increased by 57.7% to HK$34.7
2019.03.18
First Vaccine Share In Hong Kong Stock CanSinoBIO Announces Proposed Listing On The Main Board Of Hong Kong Stock Exchange
2019.02.01
CanSinoBIO Submitted NDA/BLA Application for Meningococcal Conjugate Vaccine
2019.01.14
CanSinoBIO has signed a clinical supply agreement with VaxYnethic, an Italian biotech company for human vaccine development
12